RxDoctor Payments Data

Loi Luu, MD

General Practice · Westminster, CANPI 1912961913

Payments from drug & device makers

$356in general payments, 2019–2025

Across 17 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$143
  • AstraZeneca$61
  • Alcon$49
  • Bayer$35
  • AbbVie$24
  • Amgen$18
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sun Pharmaceutical Industries Inc.4$143
AstraZeneca4$61
Alcon3$49
Bayer2$35
AbbVie1$24
Amgen1$18
Pfizer1$14
Gilead1$13

How this compares

$356 in reported general payments places this provider in the 60th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$518,939
Medicare patients
649
Services billed
5,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium388$582,150
JardianceEmpagliflozin377$325,743
ProliaDenosumab160$257,119
VascepaIcosapent Ethyl554$192,481
JanuviaSitagliptin Phosphate194$144,671
MyrbetriqMirabegron165$92,267
KerendiaFinerenone102$82,213
LinzessLinaclotide117$73,969
Evenity (2 Syringes)Romosozumab-Aqqg28$67,590
ZenpepLipase/Protease/Amylase57$65,133
TradjentaLinagliptin87$64,465
CreonLipase/Protease/Amylase41$58,797
FarxigaDapagliflozin Propanediol52$44,182
TrulicityDulaglutide36$39,755
RestasisCyclosporine52$38,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia, Evenity (2 Syringes)$18$324,709188 claims
AbbVieLinzess, Creon, Restasis$24$171,409210 claims
BayerKerendia$35$82,213102 claims
AstraZenecaFarxiga$61$44,18252 claims
GileadVemlidy$13$28,13721 claims
PfizerEliquis$14$20,63427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 12,963 general practice providers in California.

Other general practice in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →